Whenever someone tries to quit smoking, they face potent side effects of nicotine withdrawal, including cravings, increased appetite, restlessness, anxiety, irritability, and depression. There are not many medicines that offer any kind of relief from these symptoms but a diabetes drug may offer some relief. Pioglitazon, a Type II diabetes drug, targets a specific form of the peroxisome proliferator-activated receptors in the nucleus.
According to research findings, published in the Journal of Neuroscience 2019, drugs which are used to treat type II diabetes, mitigate the symptoms of nicotine withdrawal.
A new experimental research reveals that commonly used drugs to treat Type II diabetes mitigate the characteristic signs of nicotine withdrawal in rats and mice. The finding may offer an important new strategy in the battle with symptoms of nicotine withdrawal. The results of the study were published in the Journal of Neuroscience 2019.
During the demonstrations, direct injections of pioglitazone into Hippocampus of male mice reduced paw tremors, chattering, and head shakes which are the main physical signs of nicotine withdrawal. Injections of pioglitazone into the amygdala of male mice ameliorated signs of anxiety caused by nicotine withdrawal.
People who were abusing nicotine are likely to face 30 percent higher risk of developing Type II diabetes. The researchers said that people who are facing the symptoms of nicotine withdrawal, can get some relief from these symptoms with the help of drugs which are used to diagnose Type II diabetes.
Pioglitazone can be helpful not only in tackling the physical symptoms but it can also help in coping up with the emotional effects of nicotine withdrawal. The researchers suggested in the findings of the study that pioglitazone may be helpful for diabetic smokers in quitting by lessening the physical and emotional withdrawal symptoms while reducing insulin resistance.